Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 May;118(2):220–227. doi: 10.1111/j.1476-5381.1996.tb15390.x

Paracrine renal endothelin system in rats with liver cirrhosis.

B Hocher 1, R Zart 1, F Diekmann 1, P Rohmeiss 1, A Distler 1, H H Neumayer 1, C Bauer 1, P Gross 1
PMCID: PMC1909623  PMID: 8735618

Abstract

1. Liver cirrhosis was induced in rats by CCl4 administration. We analysed the expression of endothelin receptor subtypes in the renal cortex and medulla using Scatchard analysis and receptor autoradiography, and measured plasma as well as renal-tissue endothelin-1 concentrations using a specific radioimmunoassay. Furthermore, we analysed the effects of the non-selective (A/B) endothelin receptor antagonist, bosentan (6 and 100 mg kg-1 day-1) on mean arterial blood pressure, water and sodium excretion and glomerular filtration rate. 2. Our study revealed an overexpression of the endothelin B receptor (ETB) in the renal medulla of rats with liver cirrhosis (Cir: 2775 +/- 299 fmol mg-1; Con: 1695 +/- 255 fmol mg-1; n = 8; means +/- s.d., P < 0.01), whereas the density of ETB in the cortex and the endothelin A receptor (ETA) in the cortex and medulla were similar in both cirrhotic and control rats. Receptor autoradiography showed that the upregulation of medullary ETB in cirrhotic rats was due to an upregulation of ETB in the inner medullary collecting duct cells. 3. The tissue endothelin-1 concentrations were increased in the renal medulla of cirrhotic rats (Cir: 271 +/- 68 pg g-1wet wt.; Con: 153 +/- 36 pg g-1 wet wt., n = 8; means +/- s.d., P < 0.01). 4. The glomerular filtration rate was slightly decreased in cirrhotic rats but not altered after bosentan treatment in either cirrhotic or control rats. Bosentan decreased sodium excretion to a similar extent in both cirrhotic and control rats, whereas water excretion was significantly reduced by both dosages of bosentan in cirrhotic rats only (Cir + vehicle: 12.5 +/- 0.62 m day-1, Cir + 6 mg kg-1 day-1 bosentan: 8.6 +/- 1.0 ml day-1; Cir + 100 mg kg-1 day-1 bosentan: 7.4 +/- 0.6 ml day-1; n = 10; means +/- s.e.mean). 5. We therefore suggest that the upregulation of the medullary ETB in cirrhotic rats is involved in the regulation of water excretion in rats with CCl4-induced liver cirrhosis.

Full text

PDF
220

Images in this article

222Figure 1
on p.222
224Figure 5
on p.224

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  2. Arroyo V., Bernardi M., Epstein M., Henriksen J. H., Schrier R. W., Rodés J. Pathophysiology of ascites and functional renal failure in cirrhosis. J Hepatol. 1988 Apr;6(2):239–257. doi: 10.1016/s0168-8278(88)80038-2. [DOI] [PubMed] [Google Scholar]
  3. Asbert M., Ginès A., Ginès P., Jiménez W., Clària J., Saló J., Arroyo V., Rivera F., Rodés J. Circulating levels of endothelin in cirrhosis. Gastroenterology. 1993 May;104(5):1485–1491. doi: 10.1016/0016-5085(93)90360-o. [DOI] [PubMed] [Google Scholar]
  4. Bolger G. T., Liard F., Jodoin A., Jaramillo J. Vascular reactivity, tissue levels, and binding sites for endothelin: a comparison in the spontaneously hypertensive and Wistar-Kyoto rats. Can J Physiol Pharmacol. 1991 Mar;69(3):406–413. doi: 10.1139/y91-062. [DOI] [PubMed] [Google Scholar]
  5. Claria J., Jiménez W., Arroyo V., La Villa G., López C., Asbert M., Castro A., Gaya J., Rivera F., Rodés J. Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology. 1991 Feb;100(2):494–501. doi: 10.1016/0016-5085(91)90222-7. [DOI] [PubMed] [Google Scholar]
  6. Clozel M., Breu V., Gray G. A., Kalina B., Löffler B. M., Burri K., Cassal J. M., Hirth G., Müller M., Neidhart W. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994 Jul;270(1):228–235. [PubMed] [Google Scholar]
  7. Clozel M., Löffler B. M., Breu V., Hilfiger L., Maire J. P., Butscha B. Downregulation of endothelin receptors by autocrine production of endothelin-1. Am J Physiol. 1993 Jul;265(1 Pt 1):C188–C192. doi: 10.1152/ajpcell.1993.265.1.C188. [DOI] [PubMed] [Google Scholar]
  8. Clària J., Jiménez W., Arroyo V., Castro A., Asbert M., Ros J., Rivera F., Rodés J. Doses of endothelin have natriuretic effects in conscious rats with cirrhosis and ascites. Kidney Int. 1991 Aug;40(2):182–187. doi: 10.1038/ki.1991.198. [DOI] [PubMed] [Google Scholar]
  9. Clària J., Jiménez W., Ros J., Asbert M., Castro A., Arroyo V., Rivera F., Rodés J. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology. 1992 Feb;15(2):343–349. doi: 10.1002/hep.1840150227. [DOI] [PubMed] [Google Scholar]
  10. Edwards R. M., Stack E. J., Pullen M., Nambi P. Endothelin inhibits vasopressin action in rat inner medullary collecting duct via the ETB receptor. J Pharmacol Exp Ther. 1993 Dec;267(3):1028–1033. [PubMed] [Google Scholar]
  11. Eguchi S., Hirata Y., Imai T., Marumo F. C-type natriuretic peptide upregulates vascular endothelin type B receptors. Hypertension. 1994 Jun;23(6 Pt 2):936–940. doi: 10.1161/01.hyp.23.6.936. [DOI] [PubMed] [Google Scholar]
  12. Gandhi C. R., Behal R. H., Harvey S. A., Nouchi T. A., Olson M. S. Hepatic effects of endothelin. Receptor characterization and endothelin-induced signal transduction in hepatocytes. Biochem J. 1992 Nov 1;287(Pt 3):897–904. doi: 10.1042/bj2870897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gandhi C. R., Harvey S. A., Olson M. S. Hepatic effects of endothelin: metabolism of [125I]endothelin-1 by liver-derived cells. Arch Biochem Biophys. 1993 Aug 15;305(1):38–46. doi: 10.1006/abbi.1993.1390. [DOI] [PubMed] [Google Scholar]
  14. Garvin J., Sanders K. Endothelin inhibits fluid and bicarbonate transport in part by reducing Na+/K+ ATPase activity in the rat proximal straight tubule. J Am Soc Nephrol. 1991 Nov;2(5):976–982. doi: 10.1681/ASN.V25976. [DOI] [PubMed] [Google Scholar]
  15. Gellai M., DeWolf R., Pullen M., Nambi P. Distribution and functional role of renal ET receptor subtypes in normotensive and hypertensive rats. Kidney Int. 1994 Nov;46(5):1287–1294. doi: 10.1038/ki.1994.396. [DOI] [PubMed] [Google Scholar]
  16. Ginès P., Jiménez W., Arroyo V., Navasa M., López C., Titó L., Serra A., Bosch J., Sanz G., Rivera F. Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology. 1988 May-Jun;8(3):636–642. doi: 10.1002/hep.1840080333. [DOI] [PubMed] [Google Scholar]
  17. Gretz N., Ecker-Tschirner K. H., Kühnle H. F., von Dahl K., Kirschfink M., Drescher P., Lasserre J. J., Strauch M. Practicability of the inulin plasma single-shot clearance. Contrib Nephrol. 1990;81:220–228. doi: 10.1159/000418757. [DOI] [PubMed] [Google Scholar]
  18. Hocher B., Merker H. J., Dürr J. A., Schiller S., Gross P., Hensen J. Internalization of V2-vasopressin receptors in LLC-PK1-cells: evidence for receptor-mediated endocytosis. Biochem Biophys Res Commun. 1992 Aug 14;186(3):1376–1383. doi: 10.1016/s0006-291x(05)81558-x. [DOI] [PubMed] [Google Scholar]
  19. Hocher B., Rohmeiss P., Diekmann F., Zart R., Vogt V., Schiller S., Bauer C., Koppenhagen K., Distler A., Gretz N. Distribution of endothelin receptor subtypes in the rat kidney. Renal and haemodynamic effects of the mixed (A/B) endothelin receptor antagonist bosentan. Eur J Clin Chem Clin Biochem. 1995 Aug;33(8):463–472. doi: 10.1515/cclm.1995.33.8.463. [DOI] [PubMed] [Google Scholar]
  20. Hocher B., Rubens C., Hensen J., Gross P., Bauer C. Intracellular distribution of endothelin-1 receptors in rat liver cells. Biochem Biophys Res Commun. 1992 Apr 15;184(1):498–503. doi: 10.1016/0006-291x(92)91222-c. [DOI] [PubMed] [Google Scholar]
  21. Kohan D. E. Autocrine role of endothelin in rat inner medullary collecting duct: inhibition of AVP-induced cAMP accumulation. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S174–S179. doi: 10.1097/00005344-199322008-00047. [DOI] [PubMed] [Google Scholar]
  22. Kohan D. E. Endothelins in the kidney: physiology and pathophysiology. Am J Kidney Dis. 1993 Oct;22(4):493–510. doi: 10.1016/s0272-6386(12)80920-6. [DOI] [PubMed] [Google Scholar]
  23. Kohan D. E., Padilla E. Endothelin-1 production by rat inner medullary collecting duct: effect of nitric oxide, cGMP, and immune cytokines. Am J Physiol. 1994 Feb;266(2 Pt 2):F291–F297. doi: 10.1152/ajprenal.1994.266.2.F291. [DOI] [PubMed] [Google Scholar]
  24. Kourembanas S., McQuillan L. P., Leung G. K., Faller D. V. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest. 1993 Jul;92(1):99–104. doi: 10.1172/JCI116604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kuehnle H. F., von Dahl K., Schmidt F. H. Fully enzymatic inulin determination in small volume samples without deproteinization. Nephron. 1992;62(1):104–107. doi: 10.1159/000187006. [DOI] [PubMed] [Google Scholar]
  26. Kumar C., Mwangi V., Nuthulaganti P., Wu H. L., Pullen M., Brun K., Aiyar H., Morris R. A., Naughton R., Nambi P. Cloning and characterization of a novel endothelin receptor from Xenopus heart. J Biol Chem. 1994 May 6;269(18):13414–13420. [PubMed] [Google Scholar]
  27. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  28. Laffi G., Pinzani M., Meacci E., La Villa G., Renzi D., Baldi E., Cominelli F., Marra F., Gentilini P. Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites. Gastroenterology. 1989 Jan;96(1):167–177. doi: 10.1016/0016-5085(89)90777-4. [DOI] [PubMed] [Google Scholar]
  29. Leppäluoto J., Ruskoaho H. Endothelin peptides: biological activities, cellular signalling and clinical significance. Ann Med. 1992 Jun;24(3):153–161. doi: 10.3109/07853899209147813. [DOI] [PubMed] [Google Scholar]
  30. Löffler B. M., Breu V., Clozel M. Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett. 1993 Oct 25;333(1-2):108–110. doi: 10.1016/0014-5793(93)80384-7. [DOI] [PubMed] [Google Scholar]
  31. Lüscher T. F., Oemar B. S., Boulanger C. M., Hahn A. W. Molecular and cellular biology of endothelin and its receptors--Part II. J Hypertens. 1993 Feb;11(2):121–126. doi: 10.1097/00004872-199302000-00002. [DOI] [PubMed] [Google Scholar]
  32. McLean E. K., McLean A. E., Sutton P. M. Instant cirrhosis. An improved method for producing cirrhosis of the liver in rats by simultaneous administration of carbon tetrachloride and phenobarbitone. Br J Exp Pathol. 1969 Oct;50(5):502–506. [PMC free article] [PubMed] [Google Scholar]
  33. Møller S., Emmeluth C., Henriksen J. H. Elevated circulating plasma endothelin-1 concentrations in cirrhosis. J Hepatol. 1993 Sep;19(2):285–290. doi: 10.1016/s0168-8278(05)80584-7. [DOI] [PubMed] [Google Scholar]
  34. Nambi P., Pullen M., Contino L. C., Brooks D. P. Upregulation of renal endothelin receptors in rats with cyclosporine A-induced nephrotoxicity. Eur J Pharmacol. 1990 Oct 2;187(1):113–116. doi: 10.1016/0014-2999(90)90346-8. [DOI] [PubMed] [Google Scholar]
  35. Nambi P., Pullen M., Wu H. L., Aiyar N., Ohlstein E. H., Edwards R. M. Identification of endothelin receptor subtypes in human renal cortex and medulla using subtype-selective ligands. Endocrinology. 1992 Sep;131(3):1081–1086. doi: 10.1210/endo.131.3.1324149. [DOI] [PubMed] [Google Scholar]
  36. Nanji A. A., Khwaja S., Khettry U., Sadrzadeh S. M. Plasma endothelin levels in chronic ethanol fed rats: relationship to pathologic liver injury. Life Sci. 1994;54(6):423–428. doi: 10.1016/0024-3205(94)00700-4. [DOI] [PubMed] [Google Scholar]
  37. Nolan J. P. The role of endotoxin in liver injury. Gastroenterology. 1975 Dec;69(6):1346–1356. [PubMed] [Google Scholar]
  38. Roubert P., Cornet S., Plas P., Guilmard C., Pirotzky E., Chabrier P. E., Braquet P. Upregulation of renal endothelin receptors in glycerol-induced acute renal failure in the rat. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S303–S305. doi: 10.1097/00005344-199322008-00079. [DOI] [PubMed] [Google Scholar]
  39. Roubert P., Viossat I., Lonchampt M. O., Chapelat M., Schulz J., Plas P., Gillard-Roubert V., Chabrier P. E., Braquet P. Endothelin receptor regulation by endothelin synthesis in vascular smooth muscle cells: effects of dexamethasone and phosphoramidon. J Vasc Res. 1993 May-Jun;30(3):139–144. doi: 10.1159/000158988. [DOI] [PubMed] [Google Scholar]
  40. Sokolovsky M. Endothelins and sarafotoxins: physiological regulation, receptor subtypes and transmembrane signaling. Pharmacol Ther. 1992;54(2):129–149. doi: 10.1016/0163-7258(92)90030-4. [DOI] [PubMed] [Google Scholar]
  41. Teerlink J. R., Carteaux J. P., Sprecher U., Löffler B. M., Clozel M., Clozel J. P. Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am J Physiol. 1995 Jan;268(1 Pt 2):H432–H440. doi: 10.1152/ajpheart.1995.268.1.H432. [DOI] [PubMed] [Google Scholar]
  42. Triger D. R. Endotoxemia in liver disease--time for re-appraisal? J Hepatol. 1991 Mar;12(2):136–138. doi: 10.1016/0168-8278(91)90928-5. [DOI] [PubMed] [Google Scholar]
  43. Uchihara M., Izumi N., Sato C., Marumo F. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology. 1992 Jul;16(1):95–99. doi: 10.1002/hep.1840160117. [DOI] [PubMed] [Google Scholar]
  44. Vallance P., Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 1991 Mar 30;337(8744):776–778. doi: 10.1016/0140-6736(91)91384-7. [DOI] [PubMed] [Google Scholar]
  45. Vemulapalli S., Chiu P. J., Rivelli M., Foster C. J., Sybertz E. J. Modulation of circulating endothelin levels in hypertension and endotoxemia in rats. J Cardiovasc Pharmacol. 1991 Dec;18(6):895–903. doi: 10.1097/00005344-199112000-00017. [DOI] [PubMed] [Google Scholar]
  46. Warner T. D., Battistini B., Allcock G. H., Vane J. R. Endothelin ETA and ETB receptors mediate vasoconstriction and prostanoid release in the isolated kidney of the rat. Eur J Pharmacol. 1993 Dec 21;250(3):447–453. doi: 10.1016/0014-2999(93)90032-d. [DOI] [PubMed] [Google Scholar]
  47. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]
  48. Yoshimura A., Ideura T., Shirai M., Taira T., Iwasaki S., Kitaoka T., Koshikawa S. The distribution of 3H-labeled endotoxin in the kidney of liver cirrhotic rats. Scand J Urol Nephrol. 1993;27(3):295–299. doi: 10.3109/00365599309180437. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES